A presentation to: Meeting name Date

Slides:



Advertisements
Similar presentations
Minimally invasive synthetic suburethral sling operations for stress urinary incontinence in women: a Cochrane review Clinical.
Advertisements

Facts and Fiction about Type 2 Diabetes Michael L. Parchman, MD Department of Family & Community Medicine September 2004.
Copyright restrictions may apply JAMA Ophthalmology Journal Club Slides: Macular Edema After Cataract Surgery Diabetic Retinopathy Clinical Research Network.
Journal Club 1 The bigger picture. How we hope it works – Introduction – Discussion Points – Summary.
Personalised Eye Consultation (PEC) to improve outcomes in DR Dr Eva Fenwick (Research Fellow) Behavioural Research in Ophthalmology Prue Spencer, Project.
Diabetes and the Eyes Kenyon Anderson, O.D.. Blindness Risk Diabetic eye disease, caused by diabetes, is a leading cause of blindness and vision loss.
Methods for Pressure Ulcer Prevention Jeremy Doody Biomedical Engineering /6/15.
The Diabetic Retinopathy Clinical Research Network
UKHDS (UKPDS): UK Hypertension in Diabetes Study Purpose To determine whether tight control of blood pressure (aiming for BP
Applying CRASH-2 (Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage 2) in a Pre- Hospital Wilderness Context Paul B. Jones PGY1.
Vaccines for preventing influenza in healthy adults: a Cochrane review Clinical
Selenium supplementation for the primary prevention of cardiovascular disease: a Cochrane review Clinical
Date of download: 5/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Risks of Progression of Retinopathy and Vision Loss.
The Diabetic Retinopathy Clinical Research Network
Summary of “A randomized trial of standard versus intensive blood-pressure control” The SPRINT Research Group, NEJM, DOI: /NEJMoa Downloaded.
Effectiveness of yoga for hypertension: Systematic review and meta-analysis Marshall Hagins, PT, PhD1, Rebecca States,
Glossophobia.
The Diabetic Retinopathy Clinical Research Network
25 – 26 March 2013 University of Oxford Intubation or CPAP ?
Analysis of Macular Edema after Cataract Surgery in Patients with Diabetes Using Optical Coherence Tomography  Stephen J. Kim, MD, Robert Equi, MD, Neil.
A presentation to: Meeting name Date
The Diabetic Retinopathy Clinical Research Network
A presentation to: Meeting name Date
A presentation to: Meeting name Date
The Diabetic Retinopathy Clinical Research Network
A presentation to: Meeting name Date
A presentation to: Meeting name Date
Randomized Clinical Trial Jeffrey G. Gross, M.D. for the DRCR Network
Association between risk-of-bias assessments and results of randomized trials in Cochrane reviews: the ROBES study Jelena Savović1, Becky Turner2, David.
A presentation to: Meeting name Date
A presentation to: Meeting name Date
A presentation to: Meeting name Date
A presentation to: Meeting name Date
The Diabetic Retinopathy Clinical Research Network
A presentation to: Meeting name Date
A presentation to: Meeting name Date
A presentation to: Meeting name Date
A presentation to: Meeting name Date
A presentation to: Meeting name Date
A presentation to: Meeting name Date
A presentation to: Meeting name Date
A presentation to: Meeting name Date
A presentation to: Meeting name Date
A presentation to: Meeting name Date
Erratum Regarding “Preemptive Correction of Arteriovenous Access Stenosis: A Systematic Review and Meta-analysis of Randomized Controlled Trials” (Am.
A presentation to: Meeting name Date
A presentation to: Meeting name Date
A presentation to: Meeting name Date
A presentation to: Meeting name Date
A presentation to: Meeting name Date
A presentation to: Meeting name Date
A presentation to: Meeting name Date
A presentation to: Meeting name Date
Prehypertension and Incidence of ESRD: A Systematic Review and Meta-analysis  Yuli Huang, MD, Xiaoyan Cai, MD, Jianyu Zhang, MD, Weiyi Mai, MD, PhD, Sheng.
A presentation to: Meeting name Date
A presentation to: Meeting name Date
A presentation to: Meeting name Date
A presentation to: Meeting name Date
A presentation to: Meeting name Date
pulmonary embolism protocol -- EMB review
Update from education committee
A presentation to: Meeting name Date
A presentation to: Meeting name Date
A presentation to: Meeting name Date
A presentation to: Meeting name Date
Diabetic Retinopathy Clinical Research Network
Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20 536 high-risk individuals: a randomised.
FLAME Lecture: 13 Marshburn
The Diabetic Retinopathy Clinical Research Network
Diabetic Retinopathy Clinical Research Network
Presentation transcript:

A presentation to: Meeting name Date Blood pressure control for diabetic retinopathy Diana V Do, Xue Wang, Satyanarayana S Vedula, Michael Marrone, Gina Sleilati, Barbara S Hawkins, Robert N Frank Issue 1, 2015 A presentation to: Meeting name Date

Table of Contents 01 Background 02 Types of studies 03 Key results 04 Tables (Risk of Bias/Forest Plots) 05 Conclusions 06 Acknowledgements

Background Diabetes has many risk factors – including high blood pressure Diabetics often develop complications – one of which is damage to blood vessels in the back of the eye This damage is called diabetic retinopathy Question: Can diabetic retinopathy be controlled or slowed down through blood pressure control?

Types of studies Participants 15 randomized controlled trials (RCTs); 4157 type 1 diabetic participants and 9512 type 2 diabetic participants Interventions One or more anti-hypertensive agents VERSUS Placebo OR Intense blood pressure control VERSUS less intense blood pressure control

Key results “The evidence from these trials supported a benefit of more intensive blood pressure control intervention with respect to 4- to 5-year incidence of diabetic retinopathy…” RR 0.80; 95% CI 0.71 to 0.92 “The available evidence provided less support for a benefit with respect to 4- to 5-year progression of diabetic retinopathy…” RR 0.88; 95% CI 0.73 to 1.05

Key results (continued) “The available evidence regarding progression to proliferative diabetic retinopathy or clinically significant macular edema …” RR 0.95, 95% CI 0.83 to 1.09 or clinically significant macular edema “… or moderate to severe loss of best-corrected visual acuity did not support a benefit of intervention on blood pressure…” RR 1.06, 95% CI 0.85 to 1.33

Tables Risk of Bias

Tables Blood pressure control vs Tables Blood pressure control vs. no (or less) control by types of diabetes; Incidence of retinopathy at 4 to 5 years

Tables Blood pressure control vs Tables Blood pressure control vs. no (or less) control by type of diabetes; Progression of retinopathy at 4 to 5 years

Conclusions “The available evidence supports a beneficial effect of intervention to reduce blood pressure with respect to preventing diabetic retinopathy for up to 4 to 5 years.” “… the lack of evidence to support such intervention,… along with the relatively modest support for the beneficial effect on incidence, weakens the conclusion regarding an overall benefit of intervening on blood pressure solely to prevent diabetic retinopathy.”

Acknowledgements Cochrane Eyes and Vision US Satellite, funded by the National Eye Institute, National Institutes of Health Cochrane Eyes and Vision Editorial Base, funded by the UK National Health Service Research and Development Programme Systematic review conducted by Diana V Do, Xue Wang, Satyanarayana S Vedula, Michael Marrone, Gina Sleilati, Barbara S Hawkins, Robert N Frank in collaboration with methodologists at the Cochrane Eyes and Vision US Satellite Review citation Do DV, Wang X, Vedula SS, Marrone M, Sleilati G, Hawkins BS, Frank RN. Blood pressure control for diabetic retinopathy. Cochrane Database of Systematic Reviews 2015, Issue 1. Art. No.: CD006127. DOI: 10.1002/14651858.CD006127.pub2